Etranacogene Dezaparvovec

5 trials 2 recruiting NNeurology/Psychiatry Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

1 Sponsors

11 Countries

Phase III

Phase II/III

Phase I (FiH)

Phase III: 3 Phase II/III: 1 Phase I (FiH): 1

Sponsors using this IMP

CSL Behring LLC 5

All trials

5 total

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults with Hemophilia B with Pretreatment Adeno-associated Virus … Recruiting

2023-509590-23-00 Phase III 2 countries CSL Behring LLC
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe He… Recruiting

2023-505805-18-00 Phase III 4 countries CSL Behring LLC
Long-term Follow-up Study of Male Adults with Hemophilia B Previously Treated with Etranacogene Dezaparvovec (CSL222) Ended

2023-503765-37-00 Phase II/III 6 countries CSL Behring LLC
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult pat… Ended

2024-512603-39-00 Phase I (FiH) 2 countries CSL Behring LLC
A phase III trial investigating a gene therapy (AAV-hFIXco-Padua, AMT061), in adult patients with severe or moderately severe haemophilia B,… Ended

2024-510738-42-00 Phase III 6 countries CSL Behring LLC

Showing 1–5 of 5 trials

← All drugs A–Z